<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04795167</url>
  </required_header>
  <id_info>
    <org_study_id>20-001</org_study_id>
    <nct_id>NCT04795167</nct_id>
  </id_info>
  <brief_title>FLowTriever for Acute Massive Pulmonary Embolism (FLAME)</brief_title>
  <acronym>FLAME</acronym>
  <official_title>FLowTriever for Acute Massive Pulmonary Embolism (FLAME)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inari Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inari Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate treatment outcomes of patients diagnosed with high-risk (massive) pulmonary&#xD;
      embolism&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">March 16, 2021</start_date>
  <completion_date type="Anticipated">May 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Composite incidence of all-cause mortality, clinical deterioration, bailout, and major bleeding</measure>
    <time_frame>From the time of primary treatment for high-risk pulmonary embolism through hospital discharge or 45 days, which ever comes first.</time_frame>
    <description>Endpoint events will be assessed from the time of treatment of the high-risk pulmonary embolism through hospital discharge for the high-risk PE, or through 45 days post treatment for high-risk pulmonary embolism, whichever comes first..</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>PE - Pulmonary Embolism</condition>
  <condition>PE - Pulmonary Thromboembolism</condition>
  <arm_group>
    <arm_group_label>FlowTriever Arm</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Context Arm</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Prior Therapy Arm</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with high-risk (massive) pulmonary embolism.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Age &gt;=18 years Treatment team determines pulmonary embolism is the cause of shock, and the&#xD;
        PE is high-risk per the protocol definitions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Out of hospital cardiac arrest with Glasgow Coma Scale of ≤8&#xD;
&#xD;
          -  Witnessed cardiac arrest with ongoing CPR &gt;30 minutes&#xD;
&#xD;
          -  Contraindication to anticoagulants, i.e. heparin or alternative&#xD;
&#xD;
          -  Hematocrit &lt;28%&#xD;
&#xD;
          -  Platelets &lt;25,000/μL&#xD;
&#xD;
          -  INR &gt;8&#xD;
&#xD;
          -  Intracardiac thrombus and/or intracardiac clot in transit&#xD;
&#xD;
          -  Known anaphylactic sensitivity to radiographic agents that cannot be pre-treated&#xD;
&#xD;
          -  History of pulmonary hypertension with systolic pulmonary arterial pressure &gt;70 mmHg&#xD;
&#xD;
          -  Presence of chronic medical conditions with estimated &lt; 90 days life expectancy per&#xD;
             physician discretion (should not consider the current pulmonary embolism and its&#xD;
             treatment)&#xD;
&#xD;
          -  Current participation in another drug or device treatment study that, in the&#xD;
             Investigator's opinion, would interfere with participation in this study&#xD;
&#xD;
          -  Patient is known to be COVID-19 positive at hospital admission (patient has active&#xD;
             COVID-19)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitchell Silver, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>OhioHealth Riverside</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James Horowitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beaumont Royal Oak</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ascension Providence Hospital</name>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <zip>48075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gates Vascular Institute / SUNY Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lenox Hill Hospital / Northwell Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OhioHealth Riverside</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn Presbyterian/Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lankenau Medical Center / Pulmonology Associates</name>
      <address>
        <city>Wynnewood</city>
        <state>Pennsylvania</state>
        <zip>19076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inova Fairfax</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 4, 2021</study_first_submitted>
  <study_first_submitted_qc>March 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2021</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PE</keyword>
  <keyword>pulmonary embolism</keyword>
  <keyword>thromboembolism</keyword>
  <keyword>thrombectomy</keyword>
  <keyword>FlowTriever</keyword>
  <keyword>massive pulmonary embolism</keyword>
  <keyword>high risk pulmonary embolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

